Skip to main content

Craig Lindsley Archives

VU, Bristol-Myers to collaborate on Parkinson’s therapies

Sep. 21, 2012—Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.

Read more


Event celebrates Vanderbilt endowed chair holders

Aug. 30, 2012—Twelve Vanderbilt University faculty members were honored for extraordinary contributions to their respective fields during an Aug. 28 celebration of endowed chair holders at the Student Life Center.

Read more


Minds wide open: Neuroscience at Vanderbilt

Apr. 6, 2012—Vanderbilt University has emerged as one of the nation’s leading academic centers in neuroscience.

Read more


Vanderbilt expanding research enterprise into Williamson County

Mar. 9, 2012—With the addition of a new 18,000-square-foot laboratory to be located within the Cool Springs Life Sciences Center, Vanderbilt University is expanding its research enterprise into Williamson County.

Read more


New schizophrenia drug candidates entering prep for first-in-human testing

Dec. 15, 2011—The progression of new drug candidates for schizophrenia with partner Janssen Pharmaceutica is the latest evidence that a new collaborative model for drug discovery pioneered at Vanderbilt may help identify and develop innovative candidate drugs for treatment of major brain disorders.

Read more


Drug-like molecules aimed at improving treatment of Parkinson’s

Sep. 30, 2011—Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.

Read more


New drug-like molecules could improve schizophrenia treatment

Sep. 22, 2011—The discovery of new compounds that work in a fundamentally different way than those in existing schizophrenia medications may allow for more normal function of brain cells involved in schizophrenia.

Read more


Milestone in development of new treatment for ‘fragile X’

Sep. 15, 2011—Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.

Read more


Cancer study seeks clues to halting metastasis’ march

Aug. 10, 2011—Vanderbilt researchers have identified small molecules that can restore normal protein expression in human colorectal carcinoma cells and prevent invasive cancer growth.

Read more


Neuroscience drug discovery center opens at Vanderbilt

Mar. 11, 2011—Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.

Read more


Page 3 of 3123

Upcoming Events

MORE EVENTS »